- Reaction score
- 68
A little more about myristyl nicotinate.
What's interesting, a research dedicated to "myristyl nicotinate"/Nia-114 points that it acts as niacin, just much more gradually. so myristyl nicotinate probably has the same "flushing" potential. as discussed, it's critical to take "flushable" B3. to remove PGD2 from hair follicles' environment and, as a result, inhibit hair damaging process.
from the research:
"Our lead drug candidate, Nia-114 is shown in Figure 2. Nia-114 is a "prodrug" of niacin that is generated by addition of a hydrophobic "tail" to the niacin molecule. This slows down the release of Nia-114 into the living layers of the epidermis. After release into the epidermis, Nia-114 is converted back to niacin, which exerts benefit to skin. The slow release of Nia-114 into skin solves the side effect problem of niacin as a therapeutic drug by preventing the skin flushing side effects associated with free niacin."
What's interesting, a research dedicated to "myristyl nicotinate"/Nia-114 points that it acts as niacin, just much more gradually. so myristyl nicotinate probably has the same "flushing" potential. as discussed, it's critical to take "flushable" B3. to remove PGD2 from hair follicles' environment and, as a result, inhibit hair damaging process.
from the research:
"Our lead drug candidate, Nia-114 is shown in Figure 2. Nia-114 is a "prodrug" of niacin that is generated by addition of a hydrophobic "tail" to the niacin molecule. This slows down the release of Nia-114 into the living layers of the epidermis. After release into the epidermis, Nia-114 is converted back to niacin, which exerts benefit to skin. The slow release of Nia-114 into skin solves the side effect problem of niacin as a therapeutic drug by preventing the skin flushing side effects associated with free niacin."
